Clinical Value of Serum and Tissue AGR2 for Diagnosis and Prognosis in Epithelial Ovarian Cancer
Biomarkers in Medicine · 2023
DOI: 10.2217/bmm-2023-0178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomarkers in Medicine, 2023. Verfasst von Tianqing Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Institute, Fudan University, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Qingdao, 266500, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Neoplasms, Glandular and Epithelial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
To clarify the value of AGR2 for diagnosis and prognosis in epithelial ovarian cancer (EOC).
Methods
Serum AGR2 from 203 subjects were detected by ELISA, while CA125 and HE4 were determined by enhanced chemiluminescence immunoassay. The diagnostic efficacy was assessed using receiver operating characteristic curves. Tissue microarray was employed to compare tissue AGR2.
Results
Combined detection of AGR2, CA125 and HE4 improved the diagnostic specificity in the discrimination of EOC from healthy controls. Serum AGR2 was significantly higher, while CA125 and HE4 were significantly lower in EOC patients post-operatively. Low AGR2 expression may predict poorer prognosis.
Conclusion
Incorporation of AGR2 improved the specificity of CA125 and HE4 in EOC diagnosis, and may act as a tumor suppressor whose low expression in EOC patients predicted poorer outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qingdao Institute, Fudan University, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Qingdao, 266500, China.
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
ORCID-Profile: Tianqing Yan, Renquan Lu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, T., Wang, H., Ma, X., Cao, J., Tong, Y., Guo, L., & Lu, R. (2023). Clinical Value of Serum and Tissue AGR2 for Diagnosis and Prognosis in Epithelial Ovarian Cancer. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2023-0178
Vancouver
Yan T, Wang H, Ma X, Cao J, Tong Y, Guo L, et al. Clinical Value of Serum and Tissue AGR2 for Diagnosis and Prognosis in Epithelial Ovarian Cancer. Biomarkers in Medicine. 2023. doi:10.2217/bmm-2023-0178
BibTeX
@article{Yan2023,
author = {Yan, Tianqing and Wang, Haozhe and Ma, Xiaolu and Cao, Jiazhen and Tong, Ying and Guo, Lin and Lu, Renquan},
title = {Clinical Value of Serum and Tissue AGR2 for Diagnosis and Prognosis in Epithelial Ovarian Cancer},
journal = {Biomarkers in Medicine},
year = {2023},
doi = {10.2217/bmm-2023-0178}
}
EUVIMED